We are studying the safety and effectiveness of OC-1 therapy for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoma. This trial aims to understand how well the treatment works and its impact on patient survival.
Health conditions and diseases that the clinical trial is designed to study and treat.
T-cell Acute Lymphoblastic Leukemia (T-ALL) is a type of cancer that affects the blood and bone marrow, characterized by the rapid growth of immature T-cells, leading to symptoms such as fatigue, fever, and easy bruising.
T-cell Lymphoblastic Lymphoma is a rare type of cancer that originates from immature T-cells, often presenting with swollen lymph nodes, chest pain, and difficulty breathing.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.